Bausch Health Canada announces public drug plan listings for UCERIS

Bausch Health, Canada announced the first public drug plan listings for UCERIS aerosol foam to treat mild to moderate distal ulcerative colitis in adults. UCERIS is now available for patients through the public drug plans of five Canadian provinces: Ontario, Quebec, Saskatchewan, New Brunswick and Nova Scotia. These first public drug plan listings for UCERIS come following the signing of a letter of intent with the pan-Canadian Pharmaceutical Alliance early this year, setting out the parameters for listing of the treatment by the public drug plans of the provinces, territories and federal government.